Edition:
India

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

52.03USD
2:29am IST
Change (% chg)

$-0.24 (-0.46%)
Prev Close
$52.27
Open
$52.56
Day's High
$53.55
Day's Low
$50.86
Volume
176,890
Avg. Vol
213,802
52-wk High
$99.77
52-wk Low
$41.63

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $3,409.16
Shares Outstanding(Mil.): 48.39
Dividend: --
Yield (%): --

Financials

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

05 Sep 2018

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

05 Sep 2018

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

05 Sep 2018

Earnings vs. Estimates